102 related articles for article (PubMed ID: 10439954)
1. [Hypoxic bioreductive agents: the possible immune and receptor-mediated mechanisms of antitumor action].
Shchepetkin IA
Eksp Klin Farmakol; 1999; 62(3):67-74. PubMed ID: 10439954
[TBL] [Abstract][Full Text] [Related]
2. Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses.
Schepetkin I
Cancer Biother Radiopharm; 1999 Aug; 14(4):291-6. PubMed ID: 10850314
[TBL] [Abstract][Full Text] [Related]
3. Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.
Adams GE
Radiat Res; 1992 Nov; 132(2):129-39. PubMed ID: 1438693
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
5. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
6. Perfluorochemical emulsions: oxygen breathing in radiation sensitization and chemotherapy modulation.
Teicher BA; Herman TS; Frei E
Important Adv Oncol; 1992; ():39-59. PubMed ID: 1582677
[No Abstract] [Full Text] [Related]
7. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
8. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
9. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
10. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
11. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
Papadopoulou MV; Bloomer WD
Clin Cancer Res; 2003 Nov; 9(15):5714-20. PubMed ID: 14654556
[TBL] [Abstract][Full Text] [Related]
12. [Biomodulation and radiotherapy].
Bourhis J; Lartigau E
Cancer Radiother; 2000 Nov; 4 Suppl 1():128s-133s. PubMed ID: 11194950
[TBL] [Abstract][Full Text] [Related]
13. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase.
De Ridder M; Verovski VN; Chiavaroli C; Van den Berge DL; Monsaert C; Law K; Storme GA
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1473-80. PubMed ID: 17056198
[TBL] [Abstract][Full Text] [Related]
14. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
15. [Molecular design of hypoxic tumor cell-targeting drugs and imaging probes].
Tanabe K; Ito T; Nishimoto S
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1588-93. PubMed ID: 18051384
[No Abstract] [Full Text] [Related]
16. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
17. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor.
Lew YS; Kolozsvary A; Brown SL; Kim JH
Cancer Res; 2002 Aug; 62(15):4202-5. PubMed ID: 12154019
[TBL] [Abstract][Full Text] [Related]
19. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor immunoadjuvant activity and the immunoregulatory mechanisms of yeasts and their components].
Marconi P; Bistoni F
Ann Ist Super Sanita; 1982; 18(3):501-8. PubMed ID: 6765083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
